Scarica l'app Stockscreener
13.84
12.85%
-2.04
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
When (MLYS) Moves Investors should Listen - news.stocktradersdaily.com
ACC25: Mineralys' uncontrolled hypertension drug aces trial - pharmaphorum
Stifel maintains Buy on Mineralys stock with $45 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Mineralys stock with $45 target - Investing.com India
Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks
Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial - TipRanks
Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics - TipRanks
Mineralys Therapeutics Announces Late-Breaking Data from - GlobeNewswire
Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan
Mineralys Therapeutics, Inc. Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - Marketscreener.com
Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress - MSN
3 Brilliant Space Stocks to Buy Now and Hold for the Long Term - The Globe and Mail
Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.
Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
Mineralys Therapeutics to Host KOL Call to Discuss Clinical - GlobeNewswire
Mineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke Laffin - Nasdaq
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - The Manila Times
Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results - Stock Titan
MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Mineralys Therape - GuruFocus
Lorundrostat Shows Promise in Treatment of Uncontrolled and Resistant Hypertension in trials - Medical Dialogues
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Buy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety Profile - TipRanks
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MSN
Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Insider Monkey
Mineralys Therapeutics Announces Closing of Underwriters’ - GlobeNewswire
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - Marketscreener.com
Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - StockTitan
10 Pump and Dump Stocks Favored by Hedge Funds - Insider Monkey
Mineralys to present hypertension drug trial results at ACC.25 By Investing.com - Investing.com Australia
Major Investment Alert: Ra Capital Management Bets Big on Mineralys Therapeutics! - TipRanks
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - MarketScreener
Largest borrow rate increases among liquid names - TipRanks
Mineralys to present hypertension drug trial results at ACC.25 - Investing.com India
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Ex - The Manila Times
Mineralys Therapeutics to Present Phase 2 Trial Data on Lorundrostat for Uncontrolled Hypertension at ACC.25 - Nasdaq
Mineralys Therapeutics : Corporate Overview March 2025 -March 17, 2025 at 08:06 am EDT - Marketscreener.com
Major Breakthrough: New Hypertension Drug Data Earns Coveted ACC Late-Breaking Slot - StockTitan
Mineralys Therapeutics Stock (MLYS): Strategic Offering to Fuel Growth - Value the Markets
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in February 2025 - The Globe and Mail
A&O Shearman advises on the USD175 million follow-on equity offering by Mineralys Therapeutics Inc. - A&O Shearman
Mineralys Therapeutics prices $175M stock offering - MSN
Mineralys Reports Positive Results for Hypertension Drug Lorundrostat - MSN
Latham & Watkins Advises Mineralys Therapeutics on US$175 Million Underwritten Public Offering of Common Stock - Latham & Watkins LLP
Biotech Alert: Searches spiking for these stocks today - TipRanks
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Proficio Capital Partners LLC Purchases New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics Prices $175 Million Share Offering -March 12, 2025 at 03:58 am EDT - Marketscreener.com
Mineralys Therapeutics sets $13.50 share price for public offering By Investing.com - Investing.com Australia
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):